Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A deep-dive into the health economics of evolocumab after FOURIER: how cost-per-QALY models were built, what list price vs net price changes, which patients clear the value threshold, and what payers actually cover.
Read clinical reviewA deep dive into the FOURIER trial's primary and secondary endpoint results for evolocumab, including effect sizes, confidence intervals, time-course patterns, and subgroup analyses in 27,564 patients with established ASCVD.
Read clinical reviewDeep-dive into FOURIER trial pre-specified and post-hoc subgroup analyses for evolocumab, examining which patient populations saw the greatest and smallest MACE reductions by age, sex, BMI, baseline LDL-C, and more.
Read clinical reviewA deep-dive overview of the FOURIER trial, the landmark 27,564-patient RCT that proved evolocumab (a PCSK9 inhibitor) reduces heart attacks and strokes in patients already taking statins.
Read clinical reviewA deep-dive into the FOURIER trial's randomization, blinding, endpoint adjudication, statistical design, and how each methodological choice shapes interpretation of evolocumab's 15% MACE reduction.
Read clinical reviewA deep-dive into the FOURIER trial of evolocumab (Repatha) in established ASCVD, examining how the 15% MACE reduction reshaped guidelines, prescribing patterns, and patient selection for PCSK9 inhibitors.
Read clinical review